Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry Fears Report-Writing Burden From Supply Chain Risk Guidance US FDA Is Drafting

Executive Summary

As agency prepares guidance on CARES Act requirement for risk management plans to help prevent shortages of critical medicines, industry raised concerns that a broad interpretation of the “life-saving drugs” term used in the legislation could make compliance challenging.

You may also be interested in...



How US FDA Wants Pharmaceutical Production Volumes Reported For Drug Shortage Prevention

Monthly data are expected in annual reports on listed drugs and active ingredients from every registered site, starting in February.

ICH Q9 Revision Delayed By Three Months Due To COVID; Focus Spans Risk Assessments, Shortages

Extension will add training materials with goal of reducing quality defects and recalls. Revision process will also address shortage indicators related to production failures in an attempt to head off drug shortages.

USP Nitrosamine Impurities Chapter Reflects Careful Coordination With US, EU Authorities

The USP’s general chapter on nitrosamine impurities provides guidance on assessing risks and testing levels of the carcinogens in pharmaceuticals.

Topics

Related Companies

UsernamePublicRestriction

Register

PS145227

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel